SLC5A2 and congenital rubella syndrome: In addition, as for the proven nephro- and cardio-protection by both incretin mimetics [27] and sodium-glucose cotransporter-2 inhibitors [28] for type-2 diabetes patients, at least incretin mimetics could be used as an alternative to insulin in CRS patients with type-2 diabetes and without need for renal replacement therapy [27].